

April 16, 1970

Dr. Eugene L. Nowicki  
Associate Director of  
Clinical Investigation  
Lederle Laboratories  
111 West 50th Street  
New York, New York 10020

Dear Dr. Nowicki:

I have read the data on Loxapine Succinate with interest, and note that you have an extensive clinical evaluation completed. Based on this data your proposed study is reasonable.

Our study programs are focussed on the principal of evaluating the EEG profile of novel drugs, and from the profile predicting clinical applications. We are now engaged in early Phase I studies. The enclosed sample profile analysis protocol of one of our recent studies exemplifies our approach.

The proposed study is not within our interest at this time.

In the event that you have other compounds which may require Phase I evaluations, we would be pleased to review the animal data.

Thank you for your interest, and I trust we will have an opportunity to work together.

Sincerely yours,

Max Fink, M.D.  
Professor of Psychiatry

MF:kp